Island Pharmaceuticals Limited

ILA

AU0000138869

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 12:10:09 2026-01-22 am EST			5-day change	1st Jan Change
0.4300 ^AUD	-1.15%		-6.52%	-

Jan. 06	Island Pharmaceuticals says US patent granted for galidesivir in Filoviridae viruses	RE
Jan. 06	Island Pharmaceuticals Secures US Patent for Antiviral Drug Candidate; Shares Rise 12%	MT

Island Pharmaceuticals Secures Over AU$1 Million in New Funding

Published on 12/02/2025 at 10:01 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Island Pharmaceuticals Limited

Jan. 06	Island Pharmaceuticals says US patent granted for galidesivir in Filoviridae viruses	RE
Jan. 06	Island Pharmaceuticals Secures US Patent for Antiviral Drug Candidate; Shares Rise 12%	MT
Jan. 04	Island Pharmaceuticals says FDA advises it requires additional time to finalise response to co's submission	RE
Jan. 04	Island Pharmaceuticals Says US FDA Needs More Time to Review Galidesivir Submission	MT
Dec. 16	Island Pharmaceuticals Enters Master Service Agreement With Texas Biomedical to Advance Development of Antiviral Molecule	MT
Dec. 04	Island Pharmaceuticals Secures US Patent for Antiviral Drug; Shares Rise 7%	MT
Dec. 03	Island Pharmaceuticals Submits Responses to US FDA for Development of Antiviral Drug; Shares Rise 8%	MT
Dec. 03	Island Pharmaceuticals Limited Completes Additional FDA Submission to Optimise Galidesivir Development Program	CI
Dec. 02	Island Pharmaceuticals Secures Over AU$1 Million in New Funding	MT
Nov. 23	Island Pharmaceuticals Secures Membership to Medical Countermeasures Coalition, Shares Reach All-Time Peak	MT
Nov. 16	Island Pharmaceuticals Says FDA Confirms Animal Rule Pathway Appropriate for Approval of Marburg Virus Countermeasures, Shares Reach All-Time Peak	MT
Nov. 13	Island Pharmaceuticals Limited Announces Change of Address	CI
Nov. 12	Island Pharmaceuticals seeks trading halt	RE
25-10-22	Island Pharmaceuticals Says US FDA to Provide Feedback on Antiviral Drug Candidate Approval Pathway Next Month	MT
25-09-28	Island Pharmaceuticals Advances Galidesivir Approval With FDA Submission	MT
25-09-18	Island Pharmaceuticals says FDA grants co Type C meeting under galidesivir's open IND application	RE
25-09-18	Island Pharmaceuticals Says US FDA Grants Type-C Meeting Request	MT
25-09-01	Island Pharmaceuticals Lodges Request for Meeting with US FDA for Drug Candidate	MT
25-08-29	Island Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
25-07-17	Island Pharmaceuticals' Major Shareholder Increases Stake Via Exercise Option	MT
25-07-08	Island Pharmaceuticals Agrees to Acquire Antiviral Program; Shares Up 17%	MT
25-07-08	Island Pharmaceuticals announces purchase of Galidesivir antiviral program from Biocryst Pharmaceuticals	RE
25-07-06	Island pharmaceuticals seeks trading halt	RE
25-07-01	Island Pharmaceuticals Appoints Non-Executive Chairman; Shares Rise 13%	MT
25-06-09	Island Pharmaceuticals Seeks Trading Halt	RE

Chart Island Pharmaceuticals Limited

Duration

Period

ILA: Dynamic Chart

Island Pharmaceuticals Ltd is an Australia-based drug repurposing company. The Company is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.

Employees

Sector

Biotechnology & Medical Research

Calendar

Feb. 18 - Q2 2026 Earnings Release (Projected)

More about the company